Project description
Exploiting the gut microbiome for cancer diagnosis and treatment
Accumulating evidence underscores the role of the gut microbiome in health and disease, including cancer. The scope of the EU-funded ONCOBIOME project is to identify and functionally characterise the commensal bacteria of high clinical relevance. Using cohorts of more than 3 000 patients with cancer across 10 countries, project partners will identify microbiome signatures related to cancer occurrence, prognosis and response to therapy. They will also investigate the mechanistic interplay with the host metabolism, immunity and oncogenesis. Apart from fundamental knowledge, project results will lead to novel diagnostic and prognostic tests for cancer, as well as tailor-made pre- and pro-biotics.
Objective
Beyond the role the intestinal metagenome plays in regulating multiple physBeyond its role in regulating multiple physiological functions that impact health, the intestinal metagenome is implicated in cancer initiation, progression and responses to therapies, even for extraintestinal neoplasia. Hence, there is an urgent need to fully identify and functionally characterize minimalist commensal ecosystems relevant to cancer, with reliable and robust methods, to validate cancer-associated gut microbiome fingerprints of high clinical relevance, and to develop diagnosis tools that will become part of the oncological arsenal for the optimization and personalization of therapy. Based on retro-and pro-spective studies, with large discovery and validation cohorts enrolling >9,000 cancer patients across 10 countries, ancillary to ongoing innovative clinical trials or FDA/EMA approvals across 4 frequent cancer types, ONCOBIOME will pursue the following aims: 1/ identify and validate core or cancer-specific Gut OncoMicrobiome Signatures (GOMS) associated with cancer occurrence, prognosis, response to, or progression on, therapy (polychemotherapy, immune checkpoint inhibitors, dendritic cell vaccines) or adverse effects, 2/ decipher the functional relevance of these cancer-associated gut commensal ecosystems in the regulation of host metabolism, immunity and oncogenesis, 3/ integrate these GOMS with other oncology hallmarks (clinics, genomics, immunomics, metabolomics) 4/ design optimal companion tests, based on those integrated signatures to predict cancer occurrence and progression. With high carat interdisciplinary experts, ONCOBIOME expects to validate cancer or therapy-specific Gut OncoMicrobiome Signatures (GOMS) across breast, colorectal, melanoma and lung cancers adjusting for covariates, to unravel the mode of action of these GOMS in innovative platforms, thus lending support to the design of cancer preventive campaigns using well characterized pre-and pro-biotics.
Fields of science
- medical and health sciencesclinical medicineoncologylung cancer
- medical and health sciencesclinical medicineoncologyskin cancermelanoma
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- natural sciencesbiological sciencesecologyecosystems
- natural sciencesbiological sciencesmicrobiology
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
94805 Villejuif
France
See on map
Participants (22)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
94800 Villejuif
See on map
75654 Paris
See on map
38122 Trento
See on map
20133 Milan
See on map
601 77 Brno
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
656 53 Brno
See on map
91054 Erlangen
See on map
Participation ended
6525 XZ Nijmegen
See on map
10138 Torino
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
10124 Torino
See on map
CB2 1TN Cambridge
See on map
17177 Stockholm
See on map
H2XOA9 Montreal Quebec
See on map
75013 Paris
See on map
Participation ended
10117 Berlin
See on map
63263 NEU-ISENBURG
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
13288 Marseille
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
94800 Villejuif
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
69130 Ecully Cedex
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
35037 Marburg
See on map
80539 Muenchen
See on map
6525 GA Nijmegen
See on map